Proactive therapeutic drug monitoring of infliximab leads to durability of treatment in children with Inflammatory Bowel Disease

被引：0
|
作者：
Chuah, C. W. [1 ]
Eldredge, J. [1 ]
Magoffin, A. [1 ]
O'Loughlin, E., V [1 ]
Park, C. J. [2 ]
Puppi, J. [1 ]
Siew, S. [1 ,3 ]
Stormon, M. [1 ]
Thacker, K. [1 ]
Dutt, S. [1 ,3 ]
机构：
[1] Childrens Hosp Westmead, Dept Gastroenterol, Westmead, Australia
[2] Australian Natl Univ, Sydney Adventist Hosp, Clin Sch, Sch Med & Psychol, Canberra, Australia
[3] Univ Sydney, Childrens Hosp Westmead Clin Sch, Sydney Sch Med, Sydney, Australia
来源：
JOURNAL OF CROHNS & COLITIS | 2025年 / 19卷
关键词：
D O I：
10.1093/ecco-jcc/jjae190.1321
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P1147
引用
收藏
页码：i2099 / i2099
页数：1
相关论文
共 50 条
  • [41] A 3-year prospective study of a multidisciplinary early proactive therapeutic drug monitoring programme of infliximab treatments in inflammatory bowel disease
    German Sanchez-Hernandez, Jose
    Rebollo, Noemi
    Martin-Suarez, Ana
    Victoria Calvo, M.
    Munoz, Fernando
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 86 (06) : 1165 - 1175
  • [42] Proactive Therapeutic Drug Monitoring of Ustekinumab Is Associated With Increased Drug Persistence in Patients With Inflammatory Bowel Disease
    Porth, Rachel
    Deyhim, Tina
    Geeganage, Grace
    Smith, Brenden
    Zullow, Samantha
    Rabinowitz, Loren G.
    Grossberg, Laurie B.
    Cheifetz, Adam S.
    Papamichael, Konstantinos
    INFLAMMATORY BOWEL DISEASES, 2024,
  • [43] Therapeutic drug monitoring in inflammatory bowel disease
    Kopylov, Uri
    Ben-Horin, Shomron
    Seidman, Ernest
    ANNALS OF GASTROENTEROLOGY, 2014, 27 (04): : 304 - 312
  • [44] Therapeutic drug monitoring in inflammatory bowel disease
    Jossen, Jacqueline
    Dubinsky, Marla
    CURRENT OPINION IN PEDIATRICS, 2016, 28 (05) : 620 - 625
  • [45] Chronic inflammatory Bowel Disease: superior to proactive Drug Monitoring
    Franke, Katharina
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2017, 55 (12):
  • [46] Therapeutic drug monitoring was helpful in guiding the decision-making process for children receiving infliximab for inflammatory bowel disease
    Deora, Vini
    Kozak, Justin
    El-Kalla, Mohamed
    Huynh, Hien Q.
    El-Matary, Wael
    ACTA PAEDIATRICA, 2017, 106 (11) : 1863 - 1867
  • [47] COMPARISON BETWEEN PROACTIVE AND REACTIVE THERAPEUTIC DRUG MONITORING IN PEDIATRIC PATIENTS WITH INFLAMMATORY BOWEL DISEASE
    Navarro, Fernando
    Josyabhatla, Rohit
    Daniel, Rhea C.
    GASTROENTEROLOGY, 2023, 164 (06) : S499 - S499
  • [48] Usefulness of therapeutic drug monitoring of infliximab during the induction period in patients with inflammatory bowel disease
    Gil Candel, Mayte
    Gascon Canovas, Juan Jose
    Urbieta Sanz, Elena
    Gomez Espin, Rosa
    Nicolas de Prado, Isabel
    Iniesta Navalon, Carles
    REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2020, 112 (05) : 360 - 366
  • [49] Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease
    Khanna, R.
    Sattin, B. D.
    Afif, W.
    Benchimol, E. I.
    Bernard, E. -J.
    Bitton, A.
    Bressler, B.
    Fedorak, R. N.
    Ghosh, S.
    Greenberg, G. R.
    Marshall, J. K.
    Panaccione, R.
    Seidman, E. G.
    Silverberg, M. S.
    Steinhart, A. H.
    Sy, R.
    Van Assche, G.
    Walters, T. D.
    Sandborn, W. J.
    Feagan, B. G.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2013, 38 (05) : 447 - 459
  • [50] Long-Term Effectiveness and Safety of Proactive Therapeutic Drug Monitoring of Infliximab in Paediatric Inflammatory Bowel Disease: A Real-World Study
    Bautista, Susana Clemente
    Canton, Oscar Segarra
    Padulles-Zamora, Nuria
    Garcia, Sonia Garcia
    Beltran, Marina Alvarez
    Garcia, Maria Larrosa
    Poy, Maria Josep Cabanas
    Sanz-Martinez, Maria Teresa
    Vazquez, Ana
    Torner, Maria Queralt Gorgas
    Miarons, Marta
    PHARMACEUTICS, 2024, 16 (12)
12345